Taysha Gene Therapies, Inc. TSHA
4.00 USD -0.06 (-1.60%)
As ofNov 17, 2026, 2:20 PM EST
3.93 Day range 4.10
3.46 52-week range 7.30
- YTD
- -27.36%
- 1 year
- -3.03%
News
seekingalpha.com Taysha Gene Therapies, Inc. (TSHA) Q3 2026 Earnings Call Transcript Taysha Gene Therapies, Inc. ( TSHA ) Q3 2026 Earnings Call November 12, 2026 8:30 AM EST Company Participants Sean Nolan - CEO & Chairman Sukumar Nagendran - President, Head of Research & Development…
marketbeat.com Taysha Gene Therapies Q3 Earnings Call Highlights Taysha Gene Therapies NASDAQ: TSHA expects to report pivotal trial data for its experimental Rett syndrome gene therapy TSHA-102 and provide feedback from U.S. regulators on a potential filing…
benzinga.com Taysha Gene Therapies Q3 2026 Earnings Call Transcript Taysha Gene Therapies (NASDAQ:TSHA) reported third-quarter financial results on Thursday. The transcript from the company’s third-quarter earnings call has been provided below.This transcript is…
globenewswire.com Taysha Gene Therapies Reports Third Quarter 2026 Financial Results and Provides Corporate Update REVEAL pivotal and ASPIRE trials evaluating TSHA-102 for Rett syndrome ongoing; expect to report topline data from 6-month interim analysis and FDA feedback on BLA submission pathway in 1H 2027
